Search

This article, published in the Journal of the European Academy of Dermatology & Venereology, presents a case report on the rapid clinical improvement of refractory subacute cutaneous lupus erythematosus (SCLE) with the use of the oral tyrosine kinase 2 inhibitor deucravacitinib. The report highlights the challenges in treating severe cases of cutaneous lupus erythematosus (CLE) and discusses the potential of januskinase inhibition as an alternative therapy. The case study describes a 56-year-old Vietnamese patient with SCLE who showed significant improvement in symptoms after starting deucravacitinib treatment. The authors suggest that further research is needed to explore the safety, effectiveness, and tolerability of deucravacitinib in managing patients with SCLE. [Extracted from the article]

Background: Epigallocatechin‐3‐gallate (EGCG) has been proven effective in treating viral warts. Since anticarcinogenic as well as anti‐inflammatory properties are ascribed to the substance, its use has been evaluated in the context of different dermatoses. The effect of EGCG on interface dermatitis (ID), however, has not yet been explored. Objectives: In this study, we investigated the effect of EGCG on an epidermal human in vitro model of ID. Methods: Via immunohistochemistry, lesional skin of lichen planus patients and healthy skin were analysed concerning the intensity of interferon‐associated mediators, CXCL10 and MxA. Epidermal equivalents were stained analogously upon ID‐like stimulation and EGCG treatment. Monolayer keratinocytes were treated likewise and supernatants were analysed via ELISA while cells were processed for vitality assay or transcriptomic analysis. Results: CXCL10 and MxA are strongly expressed in lichen planus lesions and induced in keratinocytes upon ID‐like stimulation. EGCG reduces CXCL10 and MxA staining intensity in epidermis equivalents and CXCL10 secretion by keratinocytes upon stimulation. It furthermore minimizes the cytotoxic effect of the stimulus and downregulates a magnitude of typical pro‐inflammatory cytokines that are crucial for the perpetuation of ID. Conclusions: We provide evidence concerning anti‐inflammatory effects of EGCG within a human in vitro model of ID. The capacity to suppress mediators that are centrally involved in disease perpetuation suggests EGCG as a potential topical therapeutic in lichen planus and other autoimmune skin diseases associated with ID. [ABSTRACT FROM AUTHOR]

Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. The rash was markedly pronounced at injection sites of interferon-beta (IFN- ) administered for relapsing remitting multiple sclerosis (RRMS; see Fig. We herein describe the case of a 33-year-old male patient who presented at our emergency department with concomitant flu symptoms and a maculopapular rash. [Extracted from the article]

Effective vaccines for prevention of severe course and lethal outcome of coronavirus disease 2019 have been developed and approved in regulatory rolling and fast-track procedures; they are now widely distributed worldwide. Data about cutaneous side-effects of the new mRNA-type vaccines is scant, however. We herein report two similar cases of cutaneous adverse drug reactions (ADR) mimicking Rowell's syndrome that occurred after the first dose of BNT162b2 and mRNA-1273, respectively. Both patients achieved prompt clinical improvement with a short pulse of oral prednisolone and non-steroidal inflammatory drugs. We suspect this phenomenon to occur in a timeframe of 7-14 days after vaccination due to an interferon-γ-driven shift towards type I immunity in susceptible individuals. As rheumatic patients were excluded from phase III clinical trials and as most countries prioritized the elderly population to receive the vaccinations first, cutaneous ADR might become more frequent once the younger part of the population is vaccinated over the course of 2021. Atypical cutaneous ADR might be misinterpreted or overlooked by non-dermatologists. Further studies are required to determine the best suitable vaccine types for individual groups of patients., (© 2021 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.)

Psoriasis vulgaris and lichen planus are distinct T-cell-driven inflammatory skin diseases. Both present in a variety of clinical subtypes. Mucosal or nail involvement may be present. Here, we report the rare concomitant clinical presentation of psoriatic arthritis and annular atrophic lichen planus on the trunk of a 52-year-old male patient. Treatment with sulfasalazine failed to control inflammatory activity; methotrexate and leflunomide were ceased due to side-effects. After confirmation of both diagnoses, we initiated a tumor necrosis factor (TNF)-α-directed therapy with the fusion protein etanercept resulting in significant improvement of both conditions. This case report aims to highlight the rare colocalization of psoriasis and lichen planus, the rare entity of annular atrophic lichen planus, and to discuss a possible beneficial impact of certain TNF-α inhibitors on subtypes of lichen planus., (© 2020 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.)